» Articles » PMID: 37962868

Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry

Abstract

Bispecific antibodies as T cell engagers designed to display binding capabilities to both tumor-associated antigens and antigens on T cells are considered promising agents in the fight against cancer. Even though chemical strategies to develop such constructs have emerged, a method that readily converts a therapeutically applied antibody into a bispecific construct by a fully non-genetic process is not yet available. Herein, we report the application of a biogenic, tyrosine-based click reaction utilizing chemoenzymatic modifications of native IgG1 antibodies to generate a synthetic bispecific antibody construct that exhibits tumor-killing capability at picomolar concentrations. Control experiments revealed that a covalent linkage of the different components is required for the observed biological activities. In view of the highly potent nature of the constructs and the modular approach that relies on convenient synthetic methods utilizing therapeutically approved biomolecules, our method expedites the production of potent bispecific antibody constructs with tunable cell killing efficacy with significant impact on therapeutic properties.

Citing Articles

Construction of bispecific antibodies by specific pairing between the heavy chain and the light chain using removable SpyCatcher/SnoopCatcher units.

Yoshida J, Kato Y, Isogawa A, Tanaka Y, Kumagai I, Asano R J Biol Eng. 2024; 18(1):57.

PMID: 39402666 PMC: 11476941. DOI: 10.1186/s13036-024-00454-z.


Modular Semisynthetic Approach to Generate T Cell-Dependent Bispecific Constructs from Recombinant IgG1 Antibodies.

Shajan I, Rochet L, Tracey S, Benazza R, Jackowska B, Hernandez-Alba O Bioconjug Chem. 2024; .

PMID: 39284580 PMC: 11487494. DOI: 10.1021/acs.bioconjchem.4c00309.

References
1.
Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T . Design and Production of Bispecific Antibodies. Antibodies (Basel). 2019; 8(3). PMC: 6783844. DOI: 10.3390/antib8030043. View

2.
Shin H, Yang H, Yoon A, Lee S . Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. Int J Mol Sci. 2022; 23(10). PMC: 9146966. DOI: 10.3390/ijms23105686. View

3.
van Berkel S, van Delft F . Enzymatic strategies for (near) clinical development of antibody-drug conjugates. Drug Discov Today Technol. 2018; 30:3-10. DOI: 10.1016/j.ddtec.2018.09.005. View

4.
Lu R, Hwang Y, Liu I, Lee C, Tsai H, Li H . Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020; 27(1):1. PMC: 6939334. DOI: 10.1186/s12929-019-0592-z. View

5.
Du F, Mills E, Mao-Draayer Y . Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights. 2017; 8(1):12. PMC: 5688039. DOI: 10.1007/s13317-017-0100-y. View